JGB1741

Overview

JGB1741 (ILS-JGB-1741) is a potent and specific SIRT1 activity inhibitor with an IC 50 of ∼15 μM. JGB1741 is a weak SIRT2 and SIRT3 inhibitor with an all IC 50 >100 μM. JGB1741 increases the acetylated p53 levels leading to p53-mediated apoptosis with modulation of Bax/Bcl2 ratio, cytochrome c release and PARP cleavage. JGB1741 has the potential for breast cancer research.

Application

Products | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Sirtuin | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-111329
• CAS No.: 1256375-38-8
• Molecular Formula: C27H24N2O2S
• Molecular Weight: 440.56
• Purity: 99.37%
• Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Availability: In-stock

Source

Original product source